[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655291":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":38,"studyPopulation":34,"armGroups":39,"interventions":52,"overallOfficials":62,"centralContacts":66,"locations":76,"responsibleParty":99,"collaborators":34,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":103,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":34,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":128,"whyStopped":34,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of Oral Mucositis","The incidence of oral mucositis will be assessed according to the World Health Organization (WHO) oral mucositis grading criteria. The proportion of participants who develop oral mucositis of grade ≥1 at any time during the observation period from the day of hematopoietic stem cell transplantation (Day 0) through day 30 after transplantation (Day +30) will be compared between the intervention group and the control group.","From Day 0 to Day +30 after hematopoietic stem cell transplantation",[14],{"measure":15,"description":16,"timeFrame":12},"Severity of Oral Mucositis","The severity of oral mucositis will be evaluated according to the WHO oral mucositis grading criteria. The maximum mucositis grade and the proportion of participants who develop moderate to severe oral mucositis (grade ≥3) at any time from Day 0 through Day +30 after hematopoietic stem cell transplantation will be recorded and compared between the intervention group and the control group.",[18,21,25],{"measure":19,"description":20,"timeFrame":12},"Oral Pain Score","Oral pain intensity will be assessed using the Faces Visual Analog Scale (VAS). Pain scores will be assessed during the observation period, and the mean and peak pain scores from Day 0 through Day +30 after hematopoietic stem cell transplantation will be analyzed.",{"measure":22,"description":23,"timeFrame":24},"Salivary Inflammatory Cytokine Levels","Unstimulated saliva samples will be collected at five predefined time points during the peri-transplant period. Salivary inflammatory cytokine levels, including interleukin-6 (IL-6) and interleukin-1 beta (IL-1β), will be measured using enzyme-linked immunosorbent assay (ELISA). Changes in cytokine levels across the five time points will be evaluated, and their associations with the incidence and severity of oral mucositis will be explored.","Baseline (T0), Day 0 (T1), Day +7 (T2), Day +14 (T3), and Day +30 (T4) after hematopoietic stem cell transplantation",{"measure":26,"description":27,"timeFrame":28},"Hospital Stay and Medical Costs","The total length of hospital stay, total hospitalization costs, and the proportion of participants requiring specific treatments related to oral mucositis will be recorded and compared between the intervention group and the control group.","From Day 0 after hematopoietic stem cell transplantation to hospital discharge",{"allocation":30,"interventionModel":31,"interventionModelDescription":32,"primaryPurpose":33,"observationalModel":34,"timePerspective":34,"maskingInfo":35},"RANDOMIZED","PARALLEL","This is a randomized, controlled, parallel-group clinical trial. Eligible participants will be randomly assigned in a 1:1 ratio to receive either a standardized oral care intervention or routine oral care. Randomization will be performed using a computer-generated block randomization method with allocation concealment.","PREVENTION",null,{"masking":36,"maskingDescription":37,"whoMasked":34},"NONE","Due to the nature of the oral care intervention, masking of participants and care providers is not feasible.","Oral mucositis is one of the most frequent and clinically significant complications in pediatric patients receiving hematopoietic stem cell transplantation (HSCT). Characterized by painful inflammation and ulceration of the oral mucosa, oral mucositis can substantially impair oral intake, nutritional status, communication, and quality of life. In severe cases, it may increase the risk of bloodstream infections, require opioid analgesia, prolong hospitalization, and affect the overall course of transplantation.\n\nCurrently, preventive and supportive strategies for oral mucositis in HSCT patients mainly include oral hygiene maintenance, antimicrobial interventions, pain management, and symptomatic treatment. However, the incidence and severity of oral mucositis remain high, particularly in pediatric HSCT recipients, due to factors including intensive conditioning regimens, immature oral care behaviors, altered immune status, and changes in the oral microbiome. Therefore, effective, standardized, and feasible preventive oral care strategies are still needed.\n\nEmerging evidence suggests that maintenance of oral microbial homeostasis and improvement of oral hygiene may play important roles in reducing mucosal injury and preventing the progression of oral mucositis. However, existing oral care protocols vary considerably among institutions, and the effectiveness of comprehensive standardized oral care programs in pediatric HSCT populations requires further evaluation.\n\nThis clinical trial aims to evaluate the effectiveness of a standardized oral care intervention program for preventing and reducing oral mucositis in pediatric patients undergoing HSCT. The intervention integrates structured oral hygiene management, oral care education, adherence monitoring, and supportive oral management throughout the transplantation process.\n\nThe study is designed to provide clinical evidence regarding the role of standardized oral care in improving oral health outcomes and reducing oral mucositis-related complications in pediatric HSCT recipients. The results may contribute to establishing evidence-based oral care protocols and improving supportive care strategies for children undergoing hematopoietic stem cell transplantation.",[40,46],{"label":41,"type":42,"description":43,"interventionNames":44},"Standardized Oral Care Intervention Group","EXPERIMENTAL","Participants will receive a standardized oral care intervention during the hematopoietic stem cell transplantation period, including structured oral hygiene management, oral care education, and adherence monitoring.",[45],"Behavioral: Standardized Oral Care Intervention",{"label":47,"type":48,"description":49,"interventionNames":50},"Routine Oral Care Group","ACTIVE_COMPARATOR","Participants will receive routine oral care according to the current institutional practice during the hematopoietic stem cell transplantation period.",[51],"Behavioral: Routine Oral Care",[53,58],{"type":54,"name":55,"description":56,"armGroupLabels":57,"otherNames":34},"BEHAVIORAL","Standardized Oral Care Intervention","The intervention consists of standardized oral care procedures, including oral hygiene management, oral care education, oral moisturizing, and compliance monitoring throughout the transplantation period.",[41],{"type":54,"name":59,"description":60,"armGroupLabels":61,"otherNames":34},"Routine Oral Care","Participants will receive routine oral care provided according to institutional practice.",[47],[63],{"name":64,"affiliation":5,"role":65},"Ting Chen, PhD","PRINCIPAL_INVESTIGATOR",[67,72],{"name":68,"role":69,"phone":70,"phoneExt":34,"email":71},"Zhuoting Yuan","CONTACT","+86-18279667334","18279667334@163.com",{"name":73,"role":69,"phone":74,"phoneExt":34,"email":75},"Yan Lin","+86-19128424850","linyandent@163.com",[77],{"facility":5,"status":34,"city":78,"state":79,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":89},"Guangzhou","Guangdong","510515","China","CN",{"type":84,"coordinates":85},"Point",[86,87],113.25,23.11667,{"lat":87,"lon":86},[90,93,95,96,98],{"name":64,"role":69,"phone":91,"phoneExt":34,"email":92},"+86-020-62787939","chent@smu.edu.cn",{"name":94,"role":69,"phone":70,"phoneExt":34,"email":71},"Zhuoting yuan",{"name":64,"role":65,"phone":34,"phoneExt":34,"email":34},{"name":68,"role":97,"phone":34,"phoneExt":34,"email":34},"SUB_INVESTIGATOR",{"name":73,"role":97,"phone":34,"phoneExt":34,"email":34},{"type":100,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100655291","effect-of-a-standardized-oral-care-program-on-oral-mucositis-in-children-undergoing-hematopoietic-stem-cell-transplantation-a-randomized-controlled-trialsoc-hsct-100655291",false,"NCT07809451","Effect of a Standardized Oral Care Program on Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial(SOC-HSCT)","Systematic Oral Hygiene Intervention for the Prevention and Control of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation During the Perioperative Period: A Prospective, Randomized Controlled Clinical Trial","SOC-HSCT","Inclusion Criteria:\n\n* -Patients aged 1-18 years who undergo hematopoietic stem cell transplantation.\n* Patients scheduled to receive conditioning therapy before hematopoietic stem cell transplantation.\n* Patients and\u002For their legal guardians provide informed consent to participate in the study.\n* Patients are able to receive oral care intervention and complete oral mucositis assessments during the study period.\n\nExclusion Criteria:\n\n* Patients with pre-existing oral mucosal diseases or oral ulcers before transplantation.\n* Patients with severe systemic conditions that may interfere with oral mucositis assessment.\n* Patients who have received interventions specifically targeting oral mucositis prevention before enrollment.\n* Patients or guardians who refuse to participate or withdraw informed consent.\n* Patients who are unable to complete follow-up assessments during the study period.","ALL","1 Year","18 Years",{"count":113,"type":114},126,"ESTIMATED","INTERVENTIONAL",[117],"NA","Oral mucositis is one of the most common and debilitating complications in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). Severe oral mucositis can lead to pain, nutritional impairment, infection, prolonged hospitalization, and increased healthcare costs. This randomized controlled trial aims to evaluate whether a standardized oral care program consisting of caregiver education, supervised tooth brushing, sodium bicarbonate mouth rinsing, oral moisturizing, and compliance monitoring can reduce the incidence and severity of oral mucositis compared with routine oral care. A total of 126 pediatric HSCT recipients will be randomly assigned in a 1:1 ratio to the intervention or control group. Clinical outcomes, oral pain, inflammatory biomarkers, oral microbiota, and metabolomic profiles will be evaluated throughout the transplantation period.",[120,121],"Oral Mucositis","Hematopoietic Stem Cell Transplantation (HSCT)",[123,124,125,126,127],"Oral mucositis","Hematopoietic stem cell transplantation","Pediatric patients","Oral care","Supportive care","NOT_YET_RECRUITING","2026-09-02",{"date":131,"type":132},"2026-09-09","ACTUAL",{"date":134,"type":114},"2026-09-01",{"date":136,"type":114},"2030-09-01",{"name":5,"class":6},1]